Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid TumorsJulius Strauss, James L. Gulley, Renee N. Donahue et al.|Clinical Cancer Research|2018Cited by 415
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, William L. Dahut, David James VanderWeele et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 312
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1Andrew L. Mammen, James L. Gulley, Arun Rajan et al.|Annals of the Rheumatic Diseases|2018Cited by 134
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapiesStephanie Pitts, Renee N. Donahue|Journal of Experimental & Clinical Cancer Research|2024Cited by 25